The Latest Life Sciences Tools & Diagnostics Articles from Streetwise Reports


5 Small-Caps on Fund Manager Steve Palmer's Radar Screen

  ()
Steve Palmer, Founding Partner, President and Chief Investment Officer for AlphaNorth Asset Management, talks about a handful of companies in diverse industries that have his attention. read more >

Health Tech Firm Completes Enrollment for Female Sexual Function Trial

Research Report
  ()
A Ladenburg Thalmann report reviewed the study design and purpose. read more >

Anixa Doesn't Disappoint

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research explains why he has designated this company his 2019 stock of the year. read more >

Biotech Enters License Agreement to Validate Biomarker as Alternative NASH Diagnostic

Research Report
  ()
The background and justification for the deal was covered in an H.C. Wainwright & Co. report. read more >

Telehealth Services Provider's Positive Q3/18 Results Reflect 'Robust Growth Rate'

Research Report
  ()
A William Blair report reviewed the firm's operational and financial numbers for the period. read more >

Health Stock 'Looking Set to Bounce Back After 90% Drop'

Contributed Opinion
  ()
Technical analyst Clive Maund charts a telemedicine technology company and explains why he believes the company's stock should rebound. read more >

Biotech to Expand Precision Medicine Services via New Partnership

Research Report
  ()
A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology. read more >
News Update

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements

News Update
  ()
This Utah-based company rolled out an online campaign that highlights its strategic repositioning. read more >
Showing Results: 1 to 8 of 8

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We expect PMN to forge a licensing deal in Q2/19 or Q3/19." ❭
– André Uddin, Mackie Research Capital
"VIV signed a partnership with CSA Animal Nutrition." ❭
– Alex Koyfman, First Call
"DRRX plans to respond to a complete response letter for Posimir." ❭
– Patrick Dolezal, LifeSci Capital